Equitable Trust Co. Trims Stake in Harrow, Inc. (NASDAQ:HROW)

Equitable Trust Co. reduced its position in shares of Harrow, Inc. (NASDAQ:HROW) by 25.2% in the fourth quarter, Holdings Channel reports. The firm owned 43,555 shares of the company’s stock after selling 14,670 shares during the period. Equitable Trust Co.’s holdings in Harrow were worth $1,461,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. JPMorgan Chase & Co. grew its position in shares of Harrow by 443.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 238,367 shares of the company’s stock valued at $10,717,000 after purchasing an additional 194,480 shares in the last quarter. Oppenheimer & Co. Inc. bought a new stake in shares of Harrow during the 3rd quarter worth $1,267,000. Penserra Capital Management LLC bought a new stake in shares of Harrow during the 3rd quarter worth $1,986,000. SG Americas Securities LLC bought a new stake in shares of Harrow during the 3rd quarter worth $534,000. Finally, Semanteon Capital Management LP bought a new stake in shares of Harrow during the 3rd quarter worth $686,000. 72.76% of the stock is currently owned by hedge funds and other institutional investors.

Harrow Price Performance

Harrow stock opened at $32.00 on Tuesday. The company has a debt-to-equity ratio of 3.23, a current ratio of 1.55 and a quick ratio of 1.44. The firm has a fifty day simple moving average of $34.78 and a two-hundred day simple moving average of $39.83. Harrow, Inc. has a twelve month low of $9.30 and a twelve month high of $59.23.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on HROW. B. Riley dropped their price objective on shares of Harrow from $73.00 to $69.00 and set a “buy” rating for the company in a report on Wednesday, December 4th. HC Wainwright began coverage on shares of Harrow in a report on Thursday, February 6th. They set a “buy” rating and a $57.00 price objective for the company.

Harrow Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.